Skip directly to content

tagline 2006 December

tagline 2006

  • Activist Chides TB Congress for Complacency in Facing Drug Resistance
    "You are more invested in the DOTS model -- which has failed [to contain] multidrug-resistant TB (MDR-TB) and which is now breeding extensively drug-resistant (XDR) TB -- than you are in saving lives," Mark Harrington, Executive Director for the Treatment Action Group (TAG) told TB (tuberculosis) experts attending a symposium held by the Stop TB Partnership of the World Health Organization (WHO).
     
  • Tuberculosis Research & Development: A Critical Analysis
    TAG interviewed 100 institutions and documented the top 40 investors in TB R&D in 2005. Results highlighted in the report showed that new tools including diagnostics, drugs and vaccines received combined funding of $206 million in 2005.
     
  • How We Treat TB Today: A Talk With Gavin Churchyard
    Professor Gavin Churchyard is the director of the Aurum Institute for Health Research, which provides health care services to many mining companies in South Africa but is also an independent health research center conducting a number of important clinical trials.
     
  • TB Transmission in Healthcare Settings
    In all the news and hype about the cases of extensively drug resistant tuberculosis (XDR-TB) in KwaZulu Natal, South Africa, there has been surprisingly little discussion about how and where many of the people acquired the XDR-TB infections.
     
  • Gut Reactions
    Over the past few years, there has been renewed interest in studying the potential impact of HIV infection on CD4 T cells in the gut in the hopes of answering outstanding questions about HIV pathogenesis.
     
  • Update: Leaking LPS
    As this issue went to press, a paper appeared from Daniel Douek and colleagues reporting data which, the authors argue, further supports the model of HIV pathogenesis outlined in their Nature Immunology review.
     
  • In Brief
    • Stavudine Associated With Risk for Type-2 Diabetes
    • Generic Efavirenz/Tenofovir/FTC Combo
    • Compulsory License for Efavirenz in Thailand
    • Why Do People Still Die After Taking ARVs? Is it the Brand of Drugs?
  • GRACE Under Pressure
    Tibotec's clinical development program for the protease inhibitor darunavir (Prezista, TMC114) delivered the drug to market several months ahead of schedule. But even as it began shipping to pharmacies around the country one nagging uncertainty remained: Would darunavir be safe and effective for women?
     
  • Editorial: What's Next? Leadership Lacking in Move From 3x5 to Universal Access
    The past year saw a number of post mortems about the World Health Organization's "3x5" initiative to support countries in treating at least 50% of their HIV-infected populations in need of antiretroviral therapy.